Vigil Neuroscience, Inc. (VIGL)
$2.51
Insights on Vigil Neuroscience, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 71.8% return, outperforming this stock by 142.4%
Performance
- $2.48$3.07$2.51
1.39%
Downside
Day's Volatility :19.49%
Upside
18.35%
- $2.50$11.11$2.51
0.4%
Downside
52 Weeks Volatility :77.5%
Upside
77.41%
Returns
| Period | Vigil Neuroscience, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -7.84% | -0.2% | 0.0% |
6 Months | -11.71% | 9.7% | 0.0% |
1 Year | -70.6% | 10.6% | 0.0% |
3 Years | -76.76% | 18.5% | -22.6% |
Highlights
Market Capitalization | 119.5M |
Book Value | $2.76 |
Earnings Per Share (EPS) | -2.11 |
Wall Street Target Price | 16.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -35.24% |
Return On Equity TTM | -60.18% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -89.1M |
Diluted Eps TTM | -2.11 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.92 |
EPS Estimate Next Year | -1.92 |
EPS Estimate Current Quarter | -0.61 |
EPS Estimate Next Quarter | -0.55 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 567.33%
Technicals Summary
Sell
Neutral
Buy
Vigil Neuroscience, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Vigil Neuroscience, Inc. | 1.73% | -11.71% | -70.6% | -76.76% | -76.76% |
 Moderna, Inc. | 19.0% | 85.08% | 12.75% | -28.27% | 721.13% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.54% | 31.88% | 92.14% | 229.83% |
 Novo Nordisk A/s | 8.85% | 36.12% | 71.83% | 234.04% | 457.53% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 32.76% | 40.6% | 124.79% | 171.36% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Vigil Neuroscience, Inc. | NA | NA | NA | -1.92 | -0.6 | -0.35 | NA | 2.76 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Vigil Neuroscience, Inc. | Buy | $119.5M | -76.76% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 721.13% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 229.83% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 457.53% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 171.36% | 29.59 | 39.46% |
Institutional Holdings
Northpond Ventures, LLC
11.21%Bvf Inc
4.83%Artal Group S A
4.82%Sphera Funds Management Ltd.
4.60%Deep Track Capital, LP
4.24%683 Capital Management LLC
2.65%
Company Information
vigil neuroscience is the world’s first microglia-focused therapeutics company. our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. we are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
Organization | Vigil Neuroscience, Inc. |
Employees | 65 |
CEO | Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. |
Industry | Services |
Discover More
One Group Hospitality Inc/th
$2.51
-14.63%
Jack In The Box Inc.
$2.51
-14.63%
Telecom Argentina S.a.
$2.51
-14.63%
Rumbleon Inc
$2.51
-14.63%
Jianzhi Education Technology Group Company Ltd.
$2.51
-14.63%
Retail Opportunity Investments Corp.
$2.51
-14.63%
Kura Sushi Usa Inc-class A
$2.51
-14.63%
Paysign, Inc.
$2.51
-14.63%
Grupo Televisa, S.a.b.
$2.51
-14.63%